Global Xatmep Market

Global Xatmep Market by Dose Types (2mg/ml and 2.5mg/ml), Applications (Acute Lymphoblastic Leukemia (ALL), Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-users (Hospitals, Specialty Clinics, Others), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecasts, 2021-2028

  • Report ID: HC-3896
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 189
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global xatmep market size is anticipated to expand at a substantial CAGR during the forecast period, between 2021 and 2028. Xatmep is a metabolic inhibitor of folate analogs. Xatmep is a chemotherapy agent as well as an immune suppressant. Methotrexate is the generic name of  Xatmep. It is approved for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (PJIA). In April 2017, Azurity Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) had approved Xatmep (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution.

Global Xatmep Market summary

Market Trends, Drivers, Restraints, and Opportunities:

  • Increasing use of the oral solution in chemotherapy for pediatric patients has greatly aided in the development of novel drugs around the world, which is a driving the market.
  • Growing worldwide population, and increasing demand for pharmaceutical manufacturing drugs, are expected to drive demand for Xatmep in the coming years.
  • Rising cancer prevalence worldwide, as well as a rapidly increasing birth rate, are driving factors for the Xatmep market.
  • Growing autoimmune diseases such as active polyarticular juvenile idiopathic arthritis drive the market.
  • Rigorous FDA guidelines for new drug approval, particularly for children, and adverse effects such as mouth sores, diarrhea, nausea, vomiting, abdominal distress, fatigue after treatment hinder the global xatmep market.
  • Increasing technological innovations in generic drug treatment, rising healthcare spending are creating lucrative opportunities for market growth during the forecast period.

Scope of the report:

The report on the xatmep market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes

Details

Report Title

Xatmep Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Dose Types (2mg/ml and 2.5mg/ml), Applications (Acute Lymphoblastic Leukemia, Active Polyarticular Juvenile Idiopathic Arthritis, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), End-users (Hospitals, Specialty Clinics, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Azurity Pharmaceuticals, Inc. and Silvergate Pharmaceuticals

Xatmep Market Segment Insights:

The 2.5mg/ml segment is projected to hold a significant market share

In terms of dose types, the xatmep market is bifurcated into 2mg/ml and 2.5mg/ml. The 2.5mg/ml segment held a significant share of the market in 2020. Xatmep is approved by FDA as a commercially 2.5mg/ml dose for cancer, and autoimmune diseases. Also, xatmep oral solution, 2.5 mg/mL, is a ready-to-use product, & allowing for greater accuracy and ease of dispensing at the pharmacy is projected to drive the segment.

The acute lymphoblastic leukemia segment held a substantial market share in 2020

Based on applications, the market is fragmented into acute lymphoblastic leukemia, active polyarticular juvenile idiopathic arthritis, and others. The acute lymphoblastic leukemia segment accounts for a significant share of the market, and is projected to expand at a rapid rate during the forecast period. Xatmep is a chemotherapy agent used in cancer treatment for pediatric patients, and continuous increase in R&D in innovative drug development.

Global Xatmep Market applications

The hospital pharmacy segment to grow rapidly during the forecast period

Based on distribution channels, the market is segregated into hospital pharmacy, retail pharmacy, mail-order service, and others. The hospital pharmacy segment is expected to hold a substantial share of the market during the forecast period, owing to the global pharmaceutical industry's increased investment in R&D, rising healthcare expenditure, and increasing hospitalization cases globally.

Global Xatmep Market distribution channels

The hospitals segment to grow rapidly during the forecast period

Based on end-users, the market is segregated into hospitals, specialty clinics, and others. The hospitals segment is anticipated to hold a significant share of the market during the forecast period. Hospital segment is the market's leading service provider for cancer treatment, advanced medical facilities, growing R&D expenditure, and high patient traffic is expected to boost the segment.

North America dominates the global market

In terms of regions, the global xatmep market is split into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held a significant share of the market, due to rising prevalence of acute leukemia, and pharmaceutical companies focusing on developing novel formulations for the pediatric population. Europe held a substantial market share in the region, owing to a growing population, high healthcare spending, and improved cancer & related surgeries in the region. The market in Asia Pacific is expected to grow rapidly in the forecast periods, due to growing population, rising chronic disorders, rising government initiatives, and pharmaceutical companies to spread awareness and the presence of generic manufacture, these factors contribute to the region's market growth.

Global Xatmep Market region

Segments

Segments Covered in the Report
By Dose Types

  • 2mg/ml
  • 2.5mg/ml

By Applications

  • Acute Lymphoblastic Leukemia (ALL)
  • Active Polyarticular Juvenile Idiopathic Arthritis (PJIA)
  • Other

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Mail-order service
  • Others

By End-users

  • Hospitals
  • Specialty Clinics
  • Others

By Regions

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa

Key Players

  • Azurity Pharmaceuticals, Inc. 
  • Silvergate Pharmaceuticals

 

 

Competitive Landscape

Key players in the xatmep market include Azurity Pharmaceuticals, Inc. and Silvergate Pharmaceuticals. Global alliances and mergers and acquisitions among leading research institutes to accelerate drug discovery in the future, these companies focus on expanding their geographical presence.

Global Xatmep Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Xatmep Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Xatmep Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Xatmep Market - Supply Chain
  4.5. Global Xatmep Market Forecast
     4.5.1. Xatmep Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Xatmep Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Xatmep Market Absolute $ Opportunity
5. Global Xatmep Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Xatmep Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Xatmep Demand Share Forecast, 2019-2026
6. North America Xatmep Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Xatmep Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Xatmep Demand Share Forecast, 2019-2026
7. Latin America Xatmep Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Xatmep Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Xatmep Demand Share Forecast, 2019-2026
8. Europe Xatmep Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Xatmep Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Xatmep Demand Share Forecast, 2019-2026
9. Asia Pacific Xatmep Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Xatmep Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Xatmep Demand Share Forecast, 2019-2026
10. Middle East & Africa Xatmep Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Xatmep Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Xatmep Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Xatmep Market: Market Share Analysis
  11.2. Xatmep Distributors and Customers
  11.3. Xatmep Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Azurity Pharmaceuticals, Inc. 
     11.4.2. Silvergate Pharmaceuticals

Segments Covered in the Report
By Dose Types

  • 2mg/ml
  • 2.5mg/ml

By Applications

  • Acute Lymphoblastic Leukemia (ALL)
  • Active Polyarticular Juvenile Idiopathic Arthritis (PJIA)
  • Other

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Mail-order service
  • Others

By End-users

  • Hospitals
  • Specialty Clinics
  • Others

By Regions

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa

Key Players

  • Azurity Pharmaceuticals, Inc. 
  • Silvergate Pharmaceuticals

 

 

Key players in the xatmep market include Azurity Pharmaceuticals, Inc. and Silvergate Pharmaceuticals. Global alliances and mergers and acquisitions among leading research institutes to accelerate drug discovery in the future, these companies focus on expanding their geographical presence.

Global Xatmep Market keyplayers

Buy Report